alpha-MSH analogue raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-04. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
| Property | Value | Notes |
|---|---|---|
| Solid-state storage | -20 degrees Celsius or lower | Desiccated and protected from light |
| Solution stability | Short and method-dependent | Confirm by stability testing |
| Purity assessment | Reversed-phase HPLC | Reported as area percent |
| Identity confirmation | LC-MS or comparable method | Mass match against expected value |
| Common synonyms | MT-II; melanotan II | Informal and catalogue names |
Melanotan-2 appears on the World Anti-Doping Agency prohibited list within the peptide hormone class, and several national regulators treat it as an unapproved prescription substance. Some countries restrict importation or sale for personal use. Because the compound is widely traded as a research chemical, the practical legal picture differs between jurisdictions and shifts over time. Human safety data covering long periods are limited, and whether repeated pigmentation changes carry any lasting risk to melanocytes remains an open question.
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
Lebanon's health minister Firas Abiad stated the attacks were war crimes and part of Israel's systematic targeting of Lebanon's healthcare system. A November 2024 investigation found Israel had struck in "lethal proximity" to nineteen different hospitals in Lebanon.
Intermediate-level waste (ILW) contains higher amounts of radioactivity compared to low-level waste. It generally requires shielding, but not cooling. Intermediate-level wastes includes resins, chemical sludge and metal nuclear fuel cladding, as well as contaminated materials from reactor decommissioning. It may be solidified in concrete or bitumen or mixed with silica sand and vitrified for disposal. As a general rule, short-lived waste (mainly non-fuel materials from reactors) is buried in shallow repositories, while long-lived waste (from fuel and fuel reprocessing) is deposited in geological repository. Regulations in the United States do not define this category of waste; the term is used in Europe and elsewhere. ILW makes up 6% of all radioactive waste volume in the UK.
== History == The safety and effectiveness of donislecel was evaluated in two non-randomized, single-arm studies in which a total of 30 participants with type 1 diabetes and hypoglycemic unawareness received at least one infusion and a maximum of three infusions. Overall, 21 participants did not need to take insulin for a year or more, with eleven participants not needing insulin for one to five years and ten participants not needing insulin for more than five years. Five participants did not achieve any days of insulin independence. The FDA granted marketing approval of Lantidra to CellTrans, Inc.
=== Methods for analysis of enantiomers === Methods for measuring the two enantiomers are straightforward and include normal-phase liquid chromatography, liquid chromatography with a chiral column. However, since methods can be used to alter the two enantiomers, it may not be possible to distinguish tobacco-derived from synthetic nicotine simply by measuring the levels of the two enantiomers. A new approach uses hydrogen and deuterium nuclear magnetic resonance to distinguish tobacco-derived and synthetic nicotine based on differences the substrates used in the natural synthetic pathway performed in the tobacco plant and the substrates most used in synthesis. Another approach measures the carbon-14 content which also differs between natural and laboratory-based tobacco. These methods remain to be fully evaluated and validated using a wide range of samples.
== Regulatory status == PRP is not regulated by the FDA because, like certain other human tissue and blood products, it is exempted from the traditional regulatory pathways; any use of PRP in a clinical setting is therefore considered "off label". The medical devices used to prepare PRP, however, are subject to FDA clearance.
Sources: en.wikipedia.org
The playground features train-themed equipment with an educational plaque explaining Jones' mobile refrigeration technology. In 2022, several Black-owned breweries honored Jones during Black History Month. They released commemorative beers featuring the likeness of notable figures in Black history, including Jones.
As the solidification rate slows down, however, the area fraction of the particle-rich phase drops indicating an increase in packing efficiency. At the same time, the competitive growth process is taking place, replacing r-crystals with z-crystals. At a certain point nearing the end of the transition zone, the particle-rich phase fraction rises sharply since z-crystals are less efficient at packing particles than r-crystals. The apex of this curve marks the point where only z-crystals are present (SSZ). During steady-state growth, after the maximum particle-rich phase fraction is reached, the efficiency of packing increases as steady-state is achieved. In 2011, researchers at Yale University set out to probe the actual spatial packing of particles within the walls. Using small-angle X-ray scattering (SAXS) they characterized the particle size, shape and interparticle spacing of nominally 32 nm silica suspensions that had been freeze-cast at different speeds. Computer simulations indicated that for this system, the particles within the walls should not be touching but rather separated from one another by thin films of ice. Testing, however, revealed that the particles were, in fact, touching and more than that, they attained a packed morphology that cannot be explained by typical equilibrium densification processes.
In 1957, the SAOCGA prohibited mixed-race competitions within its member bodies. In 1959, Dennis Brutus and others founded the South African Sports Association (SASA), which campaigned to allow non-white athletes to represent South Africa. The same year, IOC delegates questioned whether SAOCGA's operation violated the Olympic Charter's ban on discrimination. Reginald Honey, South Africa's IOC member, contended that nonwhite competitors had not been selected because none were of Olympic standard, and promised that any selected in future would be given passports. Brundage felt the discrimination rule only applied at the Olympics itself, not at domestic competition, and so South Africa was allowed to compete at the 1960 Olympics in Rome. The same year, it competed at the Winter Olympics for the first time. Its delegations were all white.
trans-acting Affecting a gene or sequence on a different nucleic acid molecule or strand. A locus or sequence within a particular DNA molecule such as a chromosome is said to be trans-acting if it or its products influence or act upon other sequences located relatively far away or on an entirely different molecule or chromosome. For example, a DNA-binding protein acts "in trans" if it binds to or interacts with a sequence located on any strand or molecule different from the one on which it is encoded. Contrast cis-acting.
In a light-emitting diode, the recombination of electrons and electron holes in a semiconductor produces light (infrared, visible or UV), a process called electroluminescence. The wavelength of the light depends on the energy band gap of the semiconductors used. Since these materials have a high index of refraction, design features of the devices, such as special optical coatings and die shape, are required to efficiently emit light. Unlike a laser, the light emitted from an LED is neither spectrally nor spatially coherent nor even highly monochromatic. Its spectrum is sufficiently narrow that it appears to the human eye as a pure (saturated) color. Also, it cannot approach the very high intensity characteristic of lasers.
Sources: en.wikipedia.org
Laboratory confirmation typically combines retention time matching on a chromatographic system with mass measurement. A reference standard of known identity is needed for a meaningful comparison. Sequence-level techniques can add further confirmation.
There is no single harmonised standard governing these products, and manufacturing conditions differ. Impurities may include truncated sequences, oxidation products, residual solvents, and counter-ions. Independent testing is often the only way to characterise a given lot.
Reported studies have looked at pigmentation, photoprotection, and metabolic or appetite-related endpoints in small experimental settings. Much of the evidence base is early-stage and limited in size. Questions about long-term effects and clinical relevance remain open.
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.